PABYX
Price
$16.07
Change
-$0.04 (-0.25%)
Updated
May 23 closing price
Net Assets
2.17B
RLBCX
Price
$34.61
Change
-$0.06 (-0.17%)
Updated
May 23 closing price
Net Assets
237.69B
Interact to see
Advertisement

PABYX vs RLBCX

Header iconPABYX vs RLBCX Comparison
Open Charts PABYX vs RLBCXBanner chart's image
Putnam Dynamic Asset Allocation Bal Y
Price$16.07
Change-$0.04 (-0.25%)
VolumeN/A
Net Assets2.17B
American Funds American Balanced R3
Price$34.61
Change-$0.06 (-0.17%)
VolumeN/A
Net Assets237.69B
PABYX vs RLBCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PABYX vs. RLBCX commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PABYX is a Buy and RLBCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RLBCX has more cash in the bank: 238B vs. PABYX (2.17B). PABYX pays higher dividends than RLBCX: PABYX (2.94) vs RLBCX (1.70). PABYX was incepted earlier than RLBCX: PABYX (31 years) vs RLBCX (23 years). RLBCX (0.89) is less costly to investors than PABYX (0.68). PABYX is a more actively managed with annual turnover of: 222.00 vs. RLBCX (44.00). PABYX has a lower initial minimum investment than RLBCX: PABYX (0) vs RLBCX (250). RLBCX annual gain was more profitable for investors over the last year : 4.44 vs. PABYX (0.59). RLBCX return over 5 years is better than : 36.27 vs. PABYX (24.56).
PABYXRLBCXPABYX / RLBCX
Total Expense Ratio0.680.8976%
Annual Report Gross Expense Ratio0.680.8976%
Fund Existence31 years23 years-
Gain YTD2.2141.881118%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets2.17B238B1%
Annual Yield % from dividends2.941.70174%
Returns for 1 year0.594.4413%
Returns for 3 years17.9021.6883%
Returns for 5 years24.5636.2768%
Returns for 10 years26.9449.7254%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ULBI5.530.14
+2.60%
Ultralife Corp
RUN10.66N/A
N/A
Sunrun
AMCR9.05N/A
N/A
Amcor plc
UWMC3.97N/A
N/A
UWM Holdings Corp
LYRA0.09N/A
-1.70%
Lyra Therapeutics